FLGT

#2872
Fulgent Genetics, Inc. - Common Stock
19.5 3 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
19.29
19.61
Jahresspanne
13.46
31.04
Tagesänderung
+0.83%
Monatliche Änderung
+17.58%
6 month change
+31.25%
Jahresänderung
-17.35%
Vorheriger Schlusskurs
19.3 7
Open
19.2 9
Tief
19.2 9
Hoch
19.6 1
Volumen
47
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Fulgent Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Fulgent Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Fulgent Genetics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Fulgent Genetics, Inc. annual report, FY2025
10-K

Fulgent Genetics, Inc. current report, Q2 FY2024

Full document

Fulgent Genetics, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Fulgent Genetics, Inc. on May 16, 2024. The meeting took place at the company's principal executive offices in El Monte, California. As of the record date of March 21, 2024, there were 29,900,666 shares of common stock issued and outstanding eligible to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.

Material Changes and Voting Results

A quorum of 24,480,868 shares (approximately 82% of eligible shares) was present. The following proposals were approved:

  • Proposal 1 (Election of Directors): All four nominees were elected to serve until the 2025 Annual Meeting.
    • Ming Hsieh: 20,071,185 votes for; 314,415 votes withheld.
    • Michael Nohaile, Ph.D.: 17,462,830 votes for; 2,922,770 votes withheld.
    • Regina Groves: 17,487,701 votes for; 2,897,899 votes withheld.
    • Linda Marsh: 15,854,682 votes for; 4,530,918 votes withheld.
  • Proposal 2 (Ratification of Auditors): Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
    • Votes For: 24,238,701
    • Votes Against: 222,804
    • Votes Abstained: 19,363
  • Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on a non-binding advisory basis.
    • Votes For: 19,786,239
    • Votes Against: 573,411
    • Votes Abstained: 25,950

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Detailed descriptions of the matters voted upon are referenced in the definitive proxy statement on Schedule 14A filed on March 27, 2024.

Key Facts for Investor Verification

  • Verify the specific reasons for the significant number of votes withheld for directors Michael Nohaile, Regina Groves, and Linda Marsh.
  • Review the Schedule 14A proxy statement filed on March 27, 2024, for detailed context on the executive compensation proposal.
  • Confirm the total number of broker non-votes (4,095,268) and their impact on the voting thresholds for director elections.

Nachrichten